HEALTH● LOWJul 28 · Jul 28, 2026, 11:29 AM
Altimmune rises as GLP-1 cuts drinking in mid-stage trial
Seeking Alpha Tech
Altimmune's stock increased following positive mid-stage trial results for its GLP-1 drug, which reportedly reduced drinking. This indicates potential progress in a new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH30m agoFDA suspends food licences of IRCTC supplier, 3 ISKCON establishments in MumbaiThe HinduHEALTH46m agoANMAT banned a rodenticide throughout the country: what is the brand and what irregularities were foundClarínHEALTH50m agoThe easy and free tool for healthy agingClarínHEALTH1h agoJ & K intern doctors call off strikekashmirreader.com · India